FDA approves first once-daily eyedrop for inflammation and pain after cataract surgery
Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
ISTA expects to launch Bromday before the end of the year.
“We believe the convenience of a once-daily eyedrop will help with treatment compliance and benefit patients recovering from cataract surgery,” said Vicente Anido, Jr, PhD, president and CEO of ISTA, in a company press release.
“The recent approval of Bromday represents an important step in the evolution of ophthalmic drug delivery,” according to Robert Osher, MD, professor of ophthalmology, University of Cincinnati, and medical director emeritus, Cincinnati Eye Institute. “The fact that a potent NSAID can be effective with once daily usage will improve patient compliance while setting the pace for the rest of the industry.”
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
